Trial Profile
Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary)
- Indications Hypersomnia
- Focus Therapeutic Use
- Sponsors Cephalon
- 26 May 2010 Secondary endpoints of patient functioning and fatigue presented at the 163rd Annual Meeting of the American Psychiatric Association.
- 29 Dec 2009 Results published in the Journal of Clinical Psychiatry.
- 13 May 2009 Actual patient number (250) added as reported by ClinicalTrials.gov as reported by ClinicalTrials.gov.